Soleus Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Soleus Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-77,842	Closed	-$6.21M	–	93
2022 Q2	$6.21M	Buy	+77,842	New	+$7.37M	0.97%	34
2021 Q1	–	Sell	-12,655	Closed	-$926K	–	89
2020 Q4	$926K	Sell	12,655 -39,572	-76%	-$2.94M	0.12%	54
2020 Q3	$4.06M	Buy	52,227 +22,627	+76%	+$1.56M	2.15%	18
2020 Q2	$1.65M	Buy	+29,600	New	+$1.27M	0.94%	32

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Soleus Capital Management's HZNP Position: Q3 2022 in Review

Soleus Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 77,842 shares — an estimated $6.21M sold.

Soleus Capital Management first reported a position in HZNP in Q2 2020 and held it in 4 quarters. The position peaked at $6.21M in Q2 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Soleus Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Soleus Capital Management sold 77,842 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $6.21M.
Soleus Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 4 quarters.
Soleus Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.21M in Q2 2022.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Soleus Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.